Inhibrx Biosciences (INBX) vs Odyssey Therapeutics (ODTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Inhibrx Biosciences is the larger company by market cap ($1.02 billion vs $815.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INBX | ODTX |
|---|---|---|
| Share price | $68.97 | $16.96 |
| Market cap | $1.02B | $815.23M |
| 1-day change | -7.21% | -7.52% |
| YTD return | -12.70% | — |
| 1-year return | -17.82% | — |
| EPS (TTM) | $-9.06 | $-6.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.30M | — |
| Revenue growth (YoY) | +550.00% | — |
| Net income (latest FY) | $-140.06M | — |
| Operating margin | -10386.54% | — |
| Net margin | -10773.46% | — |
| 52-week high | $155.29 | $29.05 |
| 52-week low | $57.30 | $15.10 |
| Distance from 52-week high | -55.59% | -41.62% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +286.65% | +104.42% |
| Average volume | 305.96K | 329.31K |
| Shares outstanding | 14.77M | 48.07M |
| Employees | 109 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Inhibrx Biosciences
INBX stock →Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
INBX vs ODTX FAQ
Which is bigger, Inhibrx Biosciences or Odyssey Therapeutics?
Inhibrx Biosciences (INBX) is larger, with a market capitalization of $1.02B compared with $815.23M for Odyssey Therapeutics (ODTX).
Are Inhibrx Biosciences and Odyssey Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.